March 24, 2004 — Therics Inc. has received clearance from the U.S. Food and Drug Administration to sell a new microfabricated bone void filler for skeletal defects, according to a news release.
The extensions covered by the FDA clearance complete a new line of bone graft products offered by the Princeton, N.J.-based firm. The products feature a design of calcium salt that creates an interlocking network within the bone defect to promote healing.
Therics a subsidiary of Tredegar Corp. , has licensed its microfabrication processes from the Massachusetts Institute of Technology.